169 related articles for article (PubMed ID: 9087486)
21. [Evaluation of Colistin-Ampicillin/Sulbactam Combination Efficacy in Imipenem-Resistant Acinetobacter baumannii Strains].
Cıkman A; Ceylan MR; Parlak M; Karahocagil MK; Berktaş M
Mikrobiyol Bul; 2013 Jan; 47(1):147-51. PubMed ID: 23390912
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the E-test and conventional agar dilution methods for susceptibility testing of gram-negative anaerobic rods.
Appelbaum PC; Spangler SK; Cohen M; Jacobs MR
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):25-30. PubMed ID: 8026154
[TBL] [Abstract][Full Text] [Related]
25. Susceptibilities of 97 strains of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.
Ismaeel NA
Microbios; 1997; 91(367):97-103. PubMed ID: 9467924
[TBL] [Abstract][Full Text] [Related]
26. [In vitro activity of 9 antibiotics and 3 beta-lactamase inhibitors against 107 clinical isolates of Acinetobacter baumanii].
Echeverría MJ; López de Goicoechea MJ; Ayarza R; Vecino Y; Lazpita MA; Ibarretxebea AB; Barbier A; Cruz González M; Martínez de la Fuente P
Enferm Infecc Microbiol Clin; 1997; 15(6):319-22. PubMed ID: 9376404
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
28. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
29. Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.
Neu HC; Saha G; Chin NX
Diagn Microbiol Infect Dis; 1989; 12(3):283-5. PubMed ID: 2791491
[TBL] [Abstract][Full Text] [Related]
30. Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.
Pankuch GA; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1995 Jul; 39(7):1499-504. PubMed ID: 7492093
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
32. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
33. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
Cherubin CE; Eng RH; Smith SM; Tan EN
J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
[TBL] [Abstract][Full Text] [Related]
34. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.
Rand KH; Houck HJ
Antimicrob Agents Chemother; 2004 Aug; 48(8):2871-5. PubMed ID: 15273094
[TBL] [Abstract][Full Text] [Related]
35. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
[TBL] [Abstract][Full Text] [Related]
36. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
Jacobs MR; Aronoff SC; Johenning S; Yamabe S
J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
[TBL] [Abstract][Full Text] [Related]
37. [Evolution of antimicrobial susceptibility of Acinetobacter baumannii clinical isolates].
López-Hernández S; Alarcón T; López-Brea M
Rev Esp Quimioter; 2000 Dec; 13(4):394-400. PubMed ID: 11498706
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Livermore DM; Seetulsingh P
J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibilities of clinical Desulfovibrio isolates.
Lozniewski A; Labia R; Haristoy X; Mory F
Antimicrob Agents Chemother; 2001 Oct; 45(10):2933-5. PubMed ID: 11557495
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Appelbaum PC; Spangler SK; Jacobs MR
J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
